Evidence map›Paper›PMID 32382920›Full record

ArticleEJNMMI research2020

Targeted beta therapy of prostate cancer with

Mei-Chun Yeh, Brian W C Tse, Nicholas L Fletcher, Zachary H Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A Sokolowski, Varinder Jeet, Kristofer J Thurecht and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Role of glypican-1 in regulating multiple cellular signaling pathways.American journal of physiology. Cell physiology · 2021
    Review
  10. RetroSPECT: Gallium-67 as a Long-Lived Imaging Agent for Theranostics.Asia Oceania journal of nuclear medicine & biology · 2021
    Article
  11. Article
  12. Safety and tolerability of MiltuximabAsia Oceania journal of nuclear medicine & biology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Mei-Chun YehAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Brian W C TsePreclinical Imaging Facility, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Nicholas L FletcherCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland, Building 57 University Drive, St Lucia, Queensland, 4072, Australia.
Zachary H HoustonCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland, Building 57 University Drive, St Lucia, Queensland, 4072, Australia.
Maria LundGlytherix Ltd, Suite 2, Ground Floor 75 Talavera Road, Macquarie Park, New South Wales, 2113, Australia.
Marianna VolpertAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Chelsea StewartAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Kamil A SokolowskiPreclinical Imaging Facility, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Varinder JeetAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Kristofer J ThurechtCentre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology and ARC Training Centre in Biomedical Imaging Technology, University of Queensland, Building 57 University Drive, St Lucia, Queensland, 4072, Australia.
Douglas H CampbellGlytherix Ltd, Suite 2, Ground Floor 75 Talavera Road, Macquarie Park, New South Wales, 2113, Australia.
Bradley J WalshGlytherix Ltd, Suite 2, Ground Floor 75 Talavera Road, Macquarie Park, New South Wales, 2113, Australia.
Colleen C NelsonAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
Pamela J RussellAustralian Prostate Cancer Research Centre - Queensland, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia. pamela.russell@qut.edu.au.
Translational Research Institute · AUARC Centre of Excellence in Advanced Molecular Imaging · AUPrincess Alexandra Hospital · AUThe University of Queensland · AU

Funding

National Health and Medical Research Council APP1093539
6 · The paper itself

Abstract

purposeChimeric antibody Miltuximab®, a human IgG1 engineered from the parent antibody MIL-38, is in clinical development for solid tumour therapy. Miltuximab® targets glypican-1 (GPC-1), a cell surface protein involved in tumour growth, which is overexpressed in solid tumours, including prostate cancer (PCa). This study investigated the potential of

methodsMale BALB/c nude mice were inoculated subcutaneously with GPC-1-positive DU-145 PCa cells. In imaging and biodistribution studies, mice bearing palpable tumours received (a) 2.62 MBq [

resultsAntibody accumulation in DU-145 xenografts was detected by PET-CT imaging using [

conclusionThese findings demonstrate the potential utility of Miltuximab® as a PET imaging agent ([

Indexed as

Glypican-1MIL-38Miltuximab®Prostate cancerRadionuclide therapy

Identifiers

PMID32382920
PMCPMC7206480
OpenAlexW3022766902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.